CN104940904A - Micro-ecological modifier for cavity mucosa and preparation method of micro-ecological modifier - Google Patents
Micro-ecological modifier for cavity mucosa and preparation method of micro-ecological modifier Download PDFInfo
- Publication number
- CN104940904A CN104940904A CN201510280131.4A CN201510280131A CN104940904A CN 104940904 A CN104940904 A CN 104940904A CN 201510280131 A CN201510280131 A CN 201510280131A CN 104940904 A CN104940904 A CN 104940904A
- Authority
- CN
- China
- Prior art keywords
- mucosa
- cavity
- regulator
- micro
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a micro-ecological modifier for cavity mucosa. The micro-ecological modifier comprises the following raw materials in percentage by weight: 2%-4% of an acetic acid glacial solution with the concentration of 99.9wt%, 0.001%-0.002% of insulin, 0.001%-0.002% of glutamic acid, 0.2%-0.3% of tetradecyl dimethyl benzyl ammonium and the balance of sterile water. The micro-ecological modifier for cavity mucosa provided by the invention is significant in clinical effect, is effective, simple, convenient, practical and rapid; and according to the fundamental research, the treatment effect of the modifier on the local corresponding part of a mucosa inflammation lesion is obviously superior to those of traditional treatment methods such as blood vessel administration and oral administration.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of cavity mucosa microecologic regulator and preparation method thereof.
Background technology
Intracavity local mucous membrane pathological changes is extensively present in clinical, due to vascularity rare in mucous epithelium layer, once damage or inflammation class pathological changes locally occur mucosa, based on the particularity (such as: gastric mucosa) of lesion locations, seldom directly Local treatment can be done at mucosa infection place.See theoretically, intracavity mucosa self-healing property is very strong, can spontaneous recovery at short notice to acute mild Micro trauma or acute inflammation great majority.If but self-healing property after transferring chronic inflammatory disease to, obviously weaken, and long-time obstinate just has canceration risk.
According to the classic and clinical Therapeutic Method, be all generally treated by venous transfusion or oral administration, more severe patient needs operative treatment, and its effect is difficult to determine, therapeutic process also will be different because of individual variation.Can find out, the diversity of above-mentioned therapeutic effect makes the compliance of patient poor, and the toxic and side effects of long-term prescription is also very important in addition.Therefore, for the treatment of intracavity mucosa infection, still lack the Therapeutic Method of determined curative effect.
Summary of the invention
In order to solve the problem, the object of this invention is to provide a kind of clinical therapeutic efficacy significant cavity mucosa microecologic regulator and preparation method thereof, described regulator is accomplished effective, easy, practical, quick, is better than traditional therapy.
Above-mentioned purpose of the present invention is achieved through the following technical solutions:
A kind of cavity mucosa microecologic regulator, it is characterized in that, described regulator comprises glacial acetic acid, insulin, glutamic acid, myristyl benzyl dimethyl ammonium chloride and sterilized water;
Preferably, described regulator is made up of glacial acetic acid, insulin, glutamic acid, myristyl benzyl dimethyl ammonium chloride and sterilized water.
By weight percentage, described cavity mucosa microecologic regulator comprises glacial acetic acid solution 2-4%, insulin 0.001-0.002%, glutamic acid 0.001-0.002%, the myristyl benzyl dimethyl ammonium chloride 0.2-0.3% of 99.9 % by weight concentration, and its surplus is sterilized water;
Preferably, by weight percentage, described cavity mucosa microecologic regulator comprises glacial acetic acid solution 3%, insulin 0.001%, glutamic acid 0.001%, the myristyl benzyl dimethyl ammonium chloride 0.25% of 99.9 % by weight concentration, and its surplus is sterilized water.
The preparation method of described cavity mucosa microecologic regulator comprises the following steps: be uniformly mixed in proportion by each raw material of described regulator;
Preferably, the time of described stirring is 40 ~ 60min.
The purposes of described cavity mucosa microecologic regulator in the medicine for the preparation for the treatment of cavity mucosa infection.
Described cavity mucosa infection is mucosa in mucosa and other correlators official in mucosa, urinary tract cavity in mucosa in reproductive tract cavity, digestive tract cavity.
Described cavity mucosa microecologic regulator directly can use as lotion, and its exemplary using method comprises the following steps: for the cleaning of cavity mucosa infection place under room temperature, once a day.
Microecology rudiment, in late nineteenth century, rises abruptly in nineteen seventies, the science of the objective relation be the mankind, animal and plant and the normal microflora of self settling down interdepend, mutually restricting.Along with scientific development, people have been familiar with the complexity of human body microcosmic ecology gradually, and propose corresponding to the microecological balance of objective ecological balance theoretical-namely exist in a large number but and non-pathogenic micropopulation in body surface, cavity.These micropopulations are harmless and useful to host, possess numerous physiological effecies.This is the evolution result of normal microflora and the long-term symbiosis of its host, is also the performance of microecological balance state.If internal and external environment generation great change, this balance will be destroyed and microbial state treatment will be occurred, and cause the various types of pathological changes of host.
Present inventor takes into full account necessary material required in the various physiological environment of intracavity mucosa and mucosal tissue cell differentiation maturation process, through large component analysis and screening, develops the formula of cavity mucosa regulator of the present invention.
Find after deliberation, after cavity lining mucosa is inflamed, oozing out of inflammation produces destructive stimulus to cell, and the closedown membrane channels of now cell meeting self-protection, cell will be in anaerobic respiration state, and it is limited that this state maintains cell physiological function.Fundamental research shows, short time anaerobic respiration cell can be survived maximum 10-20 hour, and cell is belong to resting state at anaerobic state, now be beyond expression normal physiological function, after membrane channels is closed, the energy of cell cannot supply, this will cause cell disruption, Cell sap after disintegrate just becomes the best culture fluid of malignant bacteria, if can not be controlled in time, the state of an illness of leaving is carried out development and mucosal ulcer must be caused to occur, and long-term chronic inflammation obstinate will provide the hotbed grown to canceration.Therefore, inventor is in the probability taking into full account local douche and essential condition, in the formula of cavity mucosa microecologic regulator of the present invention, the effect of quaternary ammonium salt is only anti-bacteria instead of kills antibacterial, theoretical according to microecology, each local cavity mucosa has oneself profitable strain, and these antibacterials have synergism to organ physiological function; In addition, give certain nutrient substance to cell, i.e. somatomedin or aminoacid, the energy of meeting short time active cell makes it to have the ability to resist the adverse environment residing for cell and unfavorable factor; And glacial acetic acid can comprehensive adjustment mucosa local because of inflammatory seep akaline liquid thus reduce local excitation, and then for cells survival and continue differentiation and maturation create favorable conditions.
Cavity mucosa microecologic regulator clinical effectiveness of the present invention is remarkable, accomplish effective, easy, practical, quick, according to basic research, this regulator is obviously better than the traditional therapy such as blood vessel and oral administration for the therapeutic effect of corresponding position, mucosal inflammation pathological changes local.
Detailed description of the invention
Referring to specific embodiment, the present invention is described.It will be appreciated by those skilled in the art that these embodiments are only for illustration of the present invention, its scope do not limited the present invention in any way.
Experimental technique in following embodiment, if no special instructions, is conventional method.Raw material used in following embodiment, reagent material etc., if no special instructions, be commercially available purchase product.
embodiment 1
By the glacial acetic acid solution 0.01g of 95%, insulin 0.001g, glutamic acid 0.001g, myristyl benzyl dimethyl ammonium chloride 0.2g and sterilized water 99.788g, be uniformly mixed, mixing time is 40min, namely obtains cavity mucosa microecologic regulator of the present invention.
embodiment 2
By the glacial acetic acid solution 0.02g of 99.9%, insulin 0.002g, glutamic acid 0.002g, myristyl benzyl dimethyl ammonium chloride 0.3g and sterilized water 99.676g, be uniformly mixed, mixing time is 60min, namely obtains cavity mucosa microecologic regulator of the present invention.
embodiment 3
By the glacial acetic acid solution 0.03g of 97%, insulin 0.001g, glutamic acid 0.001g, myristyl benzyl dimethyl ammonium chloride 0.25g and sterilized water 99.718g, be uniformly mixed, mixing time is 50min, namely obtains cavity mucosa microecologic regulator of the present invention.
embodiment 4
The therapeutic effect contrast of different content proportioning in cavity mucosa microecologic regulator formula
Prepare cavity mucosa microecologic regulator of the present invention according to formula shown in table 1 the 1st hurdle, therapeutic effect contrast is in table 1:
Suffers from disease: genital tract mucosa inflammation, gastrointestinal mucosal inflammation, tunica mucosa urethrae femininae inflammation;
Therapentic part: inflamed mucosa;
Administration: in therapeutic room, doctor does mucosa flushing to patient;
Observe: rinse once a day, second day further consultation observing effect.
Table 1: the therapeutic effect contrast of different content proportioning in cavity mucosa microecologic regulator formula
Conclusion: through repeatedly proportioning test display: change wherein any component content and all have an impact to final effect, scheme 5 is the proportioning of optimum efficiency.
embodiment 5
The therapeutic effect contrast of different component proportioning in cavity mucosa microecologic regulator formula
Prepare cavity mucosa microecologic regulator of the present invention according to formula shown in table 2 the 1st hurdle, therapeutic effect contrast is in table 2:
Suffers from disease: genital tract mucosa inflammation, gastrointestinal mucosal inflammation, tunica mucosa urethrae femininae inflammation;
Therapentic part: inflamed mucosa;
Administration: doctor does vaginadouche to patient in therapeutic room;
Observe: rinse once a day, second day further consultation observing effect.
Table 2: the therapeutic effect contrast of different component proportioning in cavity mucosa microecologic regulator formula
Conclusion: through repeatedly proportioning test display: change wherein any component proportioning and all have an impact to final effect, scheme 4 is the proportioning of optimum efficiency.
embodiment 6
Clinical model case: female genital tract cavity mucosal inflammation adopts before and after modulators for treatment of the present invention and contrasts:
Suffers from disease: genital tract mucosa inflammation;
Therapentic part: genital tract mucosa;
Observe: rinse once a day, observing effect.
Adopt modulators for treatment of the present invention to do reproductive tract cavity mucosa the indoor doctor of gyniatrics to patient and rinse use; Treatment end is after 3 days, and get its vaginal secretions, cleannes and microbiology turbidity situation under mirror, the results are shown in Table 3:
It is as follows that laboratory, front and back inspection comparing result treated by table 3:
| Before treatment | Treat after three days |
| Secretions turbidity: (+++) | Secretions turbidity: (-) |
| Lactobacillus: (-) | Lactobacillus: (++++) |
embodiment 7
Clinical model case: digestive tract cavity mucosal inflammation adopts before and after modulators for treatment of the present invention and contrasts:
Suffers from disease: gastrointestinal mucosal inflammation;
Therapentic part: gastrointestinal mucosal;
Observe: rinse once a day, observing effect.
Adopt modulators for treatment of the present invention doctor in therapeutic room to do digestive tract to patient and rinse use; Treatment end 3 days afterwards visible mucosal inflammation is obviously disappeared, and focus is significantly improved, continual cure after 72 hours most of patient clinical cure.
embodiment 8
Clinical model case: tunica mucosa urethrae femininae inflammation adopts before and after modulators for treatment of the present invention and contrasts:
Suffers from disease: tunica mucosa urethrae femininae inflammation;
Therapentic part: tunica mucosa urethrae femininae;
Observe: rinse once a day, observing effect.
Adopt modulators for treatment of the present invention doctor in therapeutic room to do female urethra to patient and rinse use; Treat end after 1 day in table 4.
After adopting modulators for treatment of the present invention, sign alleviates and even disappears, and after 24 hours, mucosa improves clearly, and continual cure is after 48 hours, and most of patient clinical is cured substantially.
Table 4
| Before treatment | After treatment |
| Organ inflammation shows: (+++) | Treat after 24 hours: (-) |
| Patient's readme sign: (+) | Treat after 24 hours: (-) |
In a word, above specific description of embodiments of the present invention does not limit the present invention, and those skilled in the art can make various change or distortion according to the present invention, only otherwise depart from spirit of the present invention, all should belong to the scope of claims of the present invention.
Claims (6)
1. a cavity mucosa microecologic regulator, is characterized in that, described regulator comprises glacial acetic acid, insulin, glutamic acid, myristyl benzyl dimethyl ammonium chloride and sterilized water;
Preferably, described regulator is made up of glacial acetic acid, insulin, glutamic acid, myristyl benzyl dimethyl ammonium chloride and sterilized water.
2. regulator according to claim 1, it is characterized in that, by weight percentage, described regulator comprises glacial acetic acid solution 2-4%, insulin 0.001-0.002%, glutamic acid 0.001-0.002%, the myristyl benzyl dimethyl ammonium chloride 0.2-0.3% of 99.9 % by weight concentration, and surplus is sterilized water;
Preferably, by weight percentage, described regulator comprises glacial acetic acid solution 3%, insulin 0.001%, glutamic acid 0.001%, the myristyl benzyl dimethyl ammonium chloride 0.25% of 99.9 % by weight concentration, and surplus is sterilized water.
3. a preparation method for regulator as claimed in claim 1 or 2, described preparation method comprises the following steps: be uniformly mixed in proportion by each raw material of described regulator;
Preferably, the time of described stirring is 40 ~ 60min.
4. the purposes of a cavity mucosa microecologic regulator as claimed in claim 1 or 2 in the medicine for the preparation for the treatment of cavity mucosa infection.
5. purposes according to claim 4, is characterized in that, described cavity mucosa infection is mucosa in mucosa and other correlators official in mucosa, urinary tract cavity in mucosa in reproductive tract cavity, digestive tract cavity.
6. a cavity mucosa microecologic regulator as claimed in claim 1 or 2 directly can use as lotion, and its exemplary using method comprises the following steps: for the cleaning of cavity mucosa infection place under room temperature, once a day.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510280131.4A CN104940904A (en) | 2015-05-27 | 2015-05-27 | Micro-ecological modifier for cavity mucosa and preparation method of micro-ecological modifier |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510280131.4A CN104940904A (en) | 2015-05-27 | 2015-05-27 | Micro-ecological modifier for cavity mucosa and preparation method of micro-ecological modifier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104940904A true CN104940904A (en) | 2015-09-30 |
Family
ID=54156326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510280131.4A Pending CN104940904A (en) | 2015-05-27 | 2015-05-27 | Micro-ecological modifier for cavity mucosa and preparation method of micro-ecological modifier |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104940904A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412127A (en) * | 2015-11-30 | 2016-03-23 | 北京爱特普科技有限公司 | Mucosa lesion micro-ecology regulator and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103249429A (en) * | 2010-11-08 | 2013-08-14 | 希尔洛有限公司 | Buffered ophthalmic compositions and methods of use thereof |
-
2015
- 2015-05-27 CN CN201510280131.4A patent/CN104940904A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103249429A (en) * | 2010-11-08 | 2013-08-14 | 希尔洛有限公司 | Buffered ophthalmic compositions and methods of use thereof |
Non-Patent Citations (6)
| Title |
|---|
| 刘雯雯: "复方化学消毒剂中苯扎氯铵的高效液相色谱测定", 《岩矿测试》 * |
| 师海波 王克林: "《最新临床药物手册 第3版》", 31 January 2013 * |
| 柯金池: "系列季铵盐的合成和生物杀灭作用", 《广东工业大学 硕士学位论文》 * |
| 梁俊成: "局部使用胰岛素治疗皮肤粘膜溃疡52例", 《新医学》 * |
| 费叶萍: "《临床医师复习精粹 2015版》", 31 January 2015 * |
| 陈清奇: "《抗癌新药研究指南》", 28 February 2009 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412127A (en) * | 2015-11-30 | 2016-03-23 | 北京爱特普科技有限公司 | Mucosa lesion micro-ecology regulator and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105189732A (en) | Method for preventing and/or treating infections, colonisations, or illnesses related to staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis, bacteroides fragilis, staphylococcus epidermidis, propionibacterium acnes, candida albicans and/or malassezia furfur | |
| CN106309237A (en) | Hyaluronic acid private part care gel and preparation method thereof | |
| CN106728416A (en) | A kind of compound ozone oil and processing method | |
| CN102727531A (en) | Active lactic acid bacteria capsules with treatment and prevention effect on vaginitis | |
| CN106389139A (en) | Acne-removing, mark-eliminating and skin-protecting multifunctional preparation and preparation method thereof | |
| CN107519236A (en) | A kind of topical agent for treating onychomycosis | |
| CN106957811A (en) | Application of the form lactobacillus with bacteriostasis with Chinese medicine compound prescription and its in treatment gynaecological imflammation | |
| CN109985069A (en) | Probiotic composition and application thereof | |
| TWI825362B (en) | Use of lactobacillus fermentation product in preparation of external composition for enhancing skin wound healing | |
| CN104940904A (en) | Micro-ecological modifier for cavity mucosa and preparation method of micro-ecological modifier | |
| CN101297814A (en) | Emulsifiable paste for curing acne and preparation thereof | |
| CN104887715B (en) | A kind of Bacillus Subtilis Spray | |
| RU2377028C2 (en) | Vaginal mudtherapy | |
| CN105999224B (en) | A kind of biomimetic type gynaecologic washing lotion and preparation method thereof | |
| CN107308104A (en) | A kind of preparation method of gynecological gel | |
| CN107174535A (en) | A kind of hyaluronic acid compositions and application with the transdermal reparation effect of anti-inflammatory | |
| CN106309394A (en) | Metronidazole oral sticking tablets and preparation method thereof | |
| CN108904780A (en) | A kind of gynaecological gel and preparation method thereof | |
| CN101693106B (en) | Application of metallothionein on preparing medicines for treating diskal hernia and hyperosteogeny | |
| CN113995775B (en) | Probiotics foot mask with foot protection effect and preparation method thereof | |
| CN100340263C (en) | Suppository for treating bacterial vaginitis | |
| CN111658763B (en) | Gynecological antibacterial gel and preparation method thereof | |
| CN114272290B (en) | A topical compound Chinese medicinal extract for treating cancer pain of all steps, and its preparation method | |
| CN105106475A (en) | Traditional Chinese medicine gel used for treating toxin-accumulating rotting and ulcerating type bedsores during clinical nursing | |
| CN101897731A (en) | External spraying agent based on complex biological acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150930 |
|
| RJ01 | Rejection of invention patent application after publication |